A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
文献类型：期刊论文
| 作者 | Yu, Pengfei; Du, Yian; Xu, Zhiyuan; Yang, Litao; Ying, Jieer; Wang, Yongxiang; Chen, Ping; Wei, Yunhai; Xu, Hongtao; Xu, Nong |
| 刊名 | JOURNAL OF CLINICAL ONCOLOGY
 |
| 出版日期 | 2022-06-01 |
| 卷号 | 40 |
| ISSN号 | 0732-183X |
| 资助项目 | CSPC Pharmaceutical Group Co., Ltd. |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| 出版者 | LIPPINCOTT WILLIAMS & WILKINS |
| WOS记录号 | WOS:000863680301218 |
| 资助机构 | CSPC Pharmaceutical Group Co., Ltd. |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129939]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.Lishui Cent Hosp, Lishui, Peoples R China 2.Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Huzhou, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Ningbo Second Hosp, Ningbo, Peoples R China 5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yu, Pengfei,Du, Yian,Xu, Zhiyuan,et al. A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40. |
| APA | Yu, Pengfei.,Du, Yian.,Xu, Zhiyuan.,Yang, Litao.,Ying, Jieer.,...&Cheng, Xiangdong.(2022).A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection..JOURNAL OF CLINICAL ONCOLOGY,40. |
| MLA | Yu, Pengfei,et al."A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.".JOURNAL OF CLINICAL ONCOLOGY 40(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。